Multicentre evaluation of a new point-of-care test for the determination of NT-proBNP in whole blood

被引:23
作者
Zugck, Christian
Nelles, Manfred
Katus, Hugo A.
Collinson, Paul O.
Gaze, David C.
Dikkeschei, Bert
Gurr, Eberhard
Hayen, Wiebke
Haass, Markus
Hechler, Christoph
van Hoof, Viviane
Guerti, Khadija
van Waes, Carl
Printzen, Gert
Klopprogge, Kai
Schulz, Ilse
Zerback, Rainer
机构
[1] Roche Diagnost GmbH, Evaluat Near Patient Testing Dept NREA, D-68305 Mannheim, Germany
[2] Univ Klinikum Heidelberg, Abt Kardiol Angiol & Pulmonol, Heidelberg, Germany
[3] St George Hosp, London, England
[4] Isala Klin, Zwolle, Netherlands
[5] Zent Krankenhaus Links Weser, Abt Klin Chem & Zent Labor, Bremen, Germany
[6] Theresienkrankenhaus Mannheim, Mannheim, Germany
[7] Univ Ziekenhuis Antwerpen, Edegem, Belgium
[8] Inselspital Bern, Inst Klin Chem, Bern, Switzerland
[9] Exco Engn Syst Tech & Consulting GmbH, Maxdorf, Germany
关键词
analytical performance; brain natriuretic peptide (BNP); congestive heart failure; natriuretic peptides; N-terminal proBNP (NT-proBNP); point-of-care testing;
D O I
10.1515/CCLM.2006.215
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: The Roche CARDIAC proBNP point-of-care (POC) test is the first test intended for the quantitative determination of N-terminal pro-brain natriuretic peptide (NT-proBNP) in whole blood as an aid in the diagnosis of suspected congestive heart failure, in the monitoring of patients with compensated left-ventricular dysfunction and in the risk stratification of patients with acute coronary syndromes. Methods: A multicentre evaluation was carried out to assess the analytical performance of the POC NT-proBNP test at seven different sites. Results: The majority of all coefficients of variation (CVs) obtained for within-series imprecision using native blood samples was below 10% for both 52 samples measured ten times and for 674 samples measured in duplicate. Using quality control material, the majority of CV values for day-to-day imprecision were below 14% for the low control level and below 13% for the high control level. In method comparisons for four lots of the POC NT-proBNP test with the laboratory reference method (Elecsys proBNP), the slope ranged from 0.93 to 1.10 and the intercept ranged from 1.8 to 6.9. The bias found between venous and arterial blood with the POC NT-proBNP method was <= 5%. All four lots of the POC NT-proBNP test investigated showed excellent agreement, with mean differences of between -5% and +4%. No significant interference was observed with lipaemic blood (triglyceride concentrations up to 6.3 mmol/ L), icteric blood (bilirubin concentrations up to 582 mmol/ L), haemolytic blood (haemoglobin concentrations up to 62 mg/L), biotin (up to 10 mg/L), rheumatoid factor (up to 42 IU/ mL), or with 50 out of 52 standard or cardiological drugs in therapeutic concentrations. With bisoprolol and BNP, somewhat higher bias in the low NT-proBNP concentration range (< 175 ng/L) was found. Haematocrit values between 28% and 58% had no influence on the test result. Interference may be caused by human anti-mouse antibodies (HAMA) types 1 and 2. No significant influence on the results with POC NT-proBNP was found using volumes of 140 -165 mL. High NT-proBNP concentrations above the measuring range of the POC NT-proBNP test did not lead to false low results due to a potential high-dose hook effect. Conclusions: The POC NT-proBNP test showed good analytical performance and excellent agreement with the laboratory method. The POC NT-proBNP assay is therefore suitable in the POC setting.
引用
收藏
页码:1269 / 1277
页数:9
相关论文
共 30 条
[1]   N-terminal probrain natriuretic peptide (NT-proBNP) in the emergency diagnosis and in-hospital monitoring of patients with dyspnoea and ventricular dysfunction [J].
Bayés-Genís, A ;
Santaló-Bel, M ;
Zapico-Muñiz, E ;
López, L ;
Cotes, C ;
Bellido, J ;
Leta, R ;
Casan, P ;
Ordóñez-Llanos, J .
EUROPEAN JOURNAL OF HEART FAILURE, 2004, 6 (03) :301-308
[2]   NT-proBNP and BNP: biomarkers for heart failure management [J].
Bettencourt, P .
EUROPEAN JOURNAL OF HEART FAILURE, 2004, 6 (03) :359-363
[3]  
BLICK KE, 2005, POINT CARE, V4, P11
[4]   Analytical performance of the N terminal pro B type natriuretic peptide (NT-proBNP) assay on the Elecsys™ 1010 and 2010 analysers [J].
Collinson, PO ;
Barnes, SC ;
Gaze, DC ;
Galasko, G ;
Lahiri, A ;
Senior, R .
EUROPEAN JOURNAL OF HEART FAILURE, 2004, 6 (03) :365-368
[5]   Recalibration of the point-of-care test for CARDIAC T Quantitative with Elecsys Troponin T 3rd generation [J].
Collinson, PO ;
Jorgensen, B ;
Sylvén, C ;
Haass, M ;
Chwallek, F ;
Katus, HA ;
Müller-Bardorff, M ;
Derhaschnig, U ;
Hirschl, MM ;
Zerback, R .
CLINICA CHIMICA ACTA, 2001, 307 (1-2) :197-203
[6]   Multicentre evaluation of a new point-of-care test for the quantitative determination of D-dimer [J].
Dempfle, CE ;
Schraml, M ;
Besenthal, I ;
Hansen, R ;
Gehrke, J ;
Korte, W ;
Risch, M ;
Quehenberger, P ;
Handler, S ;
Minar, E ;
Schulz, I ;
Zerback, R .
CLINICA CHIMICA ACTA, 2001, 307 (1-2) :211-218
[7]  
FAIRBANKS VF, 1992, CLIN CHEM, V38, P132
[8]   N-terminal brain natriuretic peptide, but not anemia, is a powerful predictor of mortality in advanced heart failure [J].
Gardner, RS ;
Chong, KS ;
Morton, JJ ;
Mcdonagh, TA .
JOURNAL OF CARDIAC FAILURE, 2005, 11 (05) :S47-S53
[9]   Circulating erythropoietin levels and prognosis in patients with congestive heart failure - Comparison with neurohormonal and inflammatory markers [J].
George, J ;
Patal, S ;
Wexler, D ;
Abashidze, A ;
Shmilovich, H ;
Barak, T ;
Sheps, D ;
Keren, G .
ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (11) :1304-1309
[10]   Detection of left ventricular enlargement and impaired systolic function with plasma N-terminal pro brain natriuretic peptide concentrations [J].
Groenning, BA ;
Nilsson, JC ;
Sondergaard, L ;
Pedersen, F ;
Trawinski, J ;
Baumann, M ;
Larsson, HBW ;
Hildebrandt, PR .
AMERICAN HEART JOURNAL, 2002, 143 (05) :923-929